Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis

Overview

The objective of this study is to administer and validate a disease specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP).

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2020

Detailed Description

The objective of this study is to administer and validate a disease specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP). The survey items have been developed and revised from prior qualitative research with CHP patients. Patients will be recruited from WCMC and outside physician referral for the study. Patients will be asked to sign informed consent for participation. At the initial visit patients will be asked to complete the survey and two additional PROs needed for concurrent validity testing. Participants will then be asked to complete the HRQOL survey under study a second time 2 weeks after the initial visit for test-re-test reliability testing. Pulmonary function testing and six minute walk test results will be collected. Pertinent demographic and clinical information will be collected from the patients and their medical records. Psychometric testing will be performed on the overall survey instrument and the individual items in order to test validity and reliability. The goal is that the survey developed will be a reliable and valid measurement tool for use in both clinical practice and research settings.

Interventions

  • Other: Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument
    • This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.

Arms, Groups and Cohorts

  • Chronic Hypersensitivity Pneumonitis Patients

Clinical Trial Outcome Measures

Primary Measures

  • Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis
    • Time Frame: Day 0
    • The newly developed survey that is being validated consists of 42 items that assess the impact that Hypersensitivity Pneumonitis has on daily life for those who have the disease.
  • Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the Short Form (SF-12) Survey
    • Time Frame: Day 0
    • This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 12 items. The average score for this survey has been calibrated to 50 with scores below 50 indicating a below average score and scores above 50 indicating an above average score.
  • Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the King’s Brief Interstitial Lung Disease Questionnaire
    • Time Frame: Day 0
    • This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 15 items and is scored from 0-100 with 100 indicating good health.
  • Change in Health-related Quality of Life Assessment Score
    • Time Frame: 2 weeks following Day 0
    • The newly developed survey will be administered again in 2 weeks following the first assessment.

Participating in This Clinical Trial

Inclusion Criteria

  • Understand and sign the informed consent document
  • Documented diagnosis of HP made and confirmed at an ILD center via expert consensus or in multidisciplinary discussion
  • Diagnosis based upon a minimum of a medical history, physical examination, pulmonary function testing, and computerized tomography (CT) scan. Pathology will be reviewed if available but is not required.
  • HP must be the primary pulmonary disease
  • Anticipated ability to complete follow up survey within 2 weeks of initial survey completion

Exclusion Criteria

  • Non-English Speaking (Patient must be able to speak and read English fluently but it does not have to be their primary language)
  • Inability to complete questionnaire due to cognitive impairment

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Weill Medical College of Cornell University
  • Collaborator
    • Pulmonary Fibrosis Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kerri I Aronson, MD, Principal Investigator, Weill Cornell Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.